TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11035320

Group type: EXPERIMENTAL
Intervention: Prophylactic cerclage
Number of subjects: 67

Group type: COMPARATOR
Intervention: Observational group
Number of subjects: 67

Group type: COMPARATOR
Intervention: Observational group with cervical length <25 mm
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Therapeutic cerclage
Number of subjects: 67

Group type: COMPARATOR
Intervention: No cerclage (in secondary random assignment)
Number of subjects: 67
Study: 9331192

Group type: EXPERIMENTAL
Intervention: Alcohol-assisted debridement
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mechanical debridement
Number of subjects: 80
Study: 8404101

Group type: EXPERIMENTAL
Intervention: Oral administration of a polyvalent bacterial extract (BE), 7 mg from eight different bacterial strains, taken as one capsule daily for the first 10 days of 3 consecutive months.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral administration of a polyvalent bacterial extract (BE).
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 20
Study: 3807474

Group type: EXPERIMENTAL
Intervention: 6 mg piretanide with 40 mg hyoscine‐N‐butylbromide (HNB)
Number of subjects: 5

Group type: COMPARATOR
Intervention: 6 mg piretanide without HNB
Number of subjects: 5
Study: 31875494

Group type: EXPERIMENTAL
Intervention: Abstinence from alcohol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (continued usual alcohol consumption)
Number of subjects: 140
Study: 29631567

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: ACT-based stress management (ACT-bsm)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 299

Group type: COMPARATOR
Intervention: Exercise and Control groups
Number of subjects: 299
Study: 28419255

Group type: EXPERIMENTAL
Intervention: Unannounced surveys
Number of subjects: 23

Group type: COMPARATOR
Intervention: Announced surveys
Number of subjects: 23
Study: 26285704

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (RDA)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 23663152

Group type: EXPERIMENTAL
Intervention: Simplified method for complete denture fabrication
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional method for complete denture fabrication
Number of subjects: 42
Study: 21435970

Group type: EXPERIMENTAL
Intervention: Overlay group (augmented reality image overlay and laser guidance)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (classical freehand insertions)
Number of subjects: 40
Study: 18644424

Group type: EXPERIMENTAL
Intervention: EMG-triggered neuromuscular electrical stimulation (NMES; EMG-stim) applied to the wrist extensor for two sessions (30 min/session) a day, five times per week for 10 weeks.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 14
Study: 16431002

Group type: EXPERIMENTAL
Intervention: Kaneka Q10 300 mg/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Kaneka Q10 600 mg/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Kaneka Q10 900 mg/day
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 12783234

Group type: EXPERIMENTAL
Intervention: Saliva cortisol (C) during competition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Saliva testosterone (T) during competition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Saliva cortisol (C) during recovery period
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Saliva testosterone (T) during recovery period
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: T/C ratio during recovery period
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recovery period duration
Number of subjects: 20
Study: 10791524

Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (46 Gy)
Number of subjects: 715

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 715
Study: 9279065

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 0
Study: 7901059

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g oral dose)
Number of subjects: 100
Study: 3528725

Group type: EXPERIMENTAL
Intervention: Naftidrofurylhydrogenoxalate (Dusodril) as adjunctive therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (dextran‐40 infusions)
Number of subjects: 60
Study: 29565630

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aromatherapy inhalation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage and inhalation
Number of subjects: 60
Study: 28253062

Group type: EXPERIMENTAL
Intervention: Positive feedback
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Autonomy-supportive style
Number of subjects: 120

Group type: COMPARATOR
Intervention: Negative feedback
Number of subjects: 120

Group type: COMPARATOR
Intervention: Controlling style
Number of subjects: 120
Study: 23631746

Group type: EXPERIMENTAL
Intervention: Free gingival graft (FGG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Maintenance (M) group (Control)
Number of subjects: 60
Study: 23650781

Group type: EXPERIMENTAL
Intervention: Ribavirin-pegylated interferon alpha 2a
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vitamin D control group (healthy subjects)
Number of subjects: 50
Study: 20883981

Group type: EXPERIMENTAL
Intervention: Group Lifestyle Triple P
Number of subjects: 101

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 101
Study: 18037598

Group type: EXPERIMENTAL
Intervention: Improved high-performance liquid chromatography method with fluorescence detection (HPLC-FLU) for quantification of tamoxifen and metabolites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single stage liquid-liquid extraction method
Number of subjects: 0
Study: 16831798

Group type: EXPERIMENTAL
Intervention: Educational visits by a trained nurse (single 40-minute visit)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Educational visits by a trained nurse (single 40-minute visit) among non-smoking physicians
Number of subjects: 523

Group type: COMPARATOR
Intervention: Control group (no visit)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Control group (no visit) among non-smoking physicians
Number of subjects: 523
Study: 12730475

Group type: EXPERIMENTAL
Intervention: Iron and folate supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil and vitamins E and C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin A and beta-carotene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional advice, magnesium, fish oil and zinc supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific nutrient supplementation
Number of subjects: 0
Study: 10750851

Group type: EXPERIMENTAL
Intervention: Open application model with supervised washing and at-home use of test products.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Washing with surfactants on the dorsal hand and volar forearm.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Squamometry as an assessment method.
Number of subjects: 0
Study: 8911878

Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms three times daily, total dose 150 micrograms)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Octreotide (62.5 micrograms continuous infusion 24/h)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Octreotide (112.5 micrograms continuous infusion 24/h)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Octreotide (113 micrograms continuous infusion)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Octreotide (all doses)
Number of subjects: 7
Study: 1816439

Group type: EXPERIMENTAL
Intervention: Captopril, 50 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prazosin, 2 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg
Number of subjects: 60
Study: 6125198

Group type: EXPERIMENTAL
Intervention: Sustained release aminophylline tablets
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled rimiterol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30247640

Group type: EXPERIMENTAL
Intervention: 6-month intervention (n=30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual care (n=31)
Number of subjects: 61
Study: 27914903

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytical therapy
Number of subjects: 470

Group type: COMPARATOR
Intervention: Brief psychosocial intervention
Number of subjects: 470
Study: 26432671

Group type: EXPERIMENTAL
Intervention: Statin users (15% of hypertensive subjects, >3 months use)
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: Statin users (79% of diabetic subjects, high-sodium diet)
Number of subjects: 1265
Study: 23631970

Group type: EXPERIMENTAL
Intervention: Jasper jumper appliance followed by fixed appliances
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Activator-headgear combination followed by fixed appliances
Number of subjects: 72

Group type: COMPARATOR
Intervention: Untreated subjects (control group)
Number of subjects: 72
Study: 21810115

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Diclofenac (Control in CONDOR)
Number of subjects: 1000
Study: 19343426

Group type: EXPERIMENTAL
Intervention: Incidental finding (metastatic gallbladder cancer)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Iatrogenic injury (common bile duct injury)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Senior residents (PGY4-PGY5)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All residents
Number of subjects: 15
Study: 16924007

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 155

Group type: COMPARATOR
Intervention: Endovascular treatment
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: SAH patients
Number of subjects: 155
Study: 14991686

Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg from Medley SA Indústria Farmacêutica (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lexotan 6 mg from Produtos Roche Químico e Farmacêutico SA (reference formulation)
Number of subjects: 24
Study: 11713622

Group type: EXPERIMENTAL
Intervention: 0.125 mg triazolam
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.0 mg (placebo)
Number of subjects: 40
Study: 9392465

Group type: EXPERIMENTAL
Intervention: Detailed information before MRM (n=144)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Routine information before MRM (n=189)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Standard MRI (n=5837)
Number of subjects: 336
Study: 7491369

Group type: EXPERIMENTAL
Intervention: Sertraline or Imipramine (SSRI or tricyclic antidepressant)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Imipramine (150 mg/day for at least 4 consecutive weeks)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Chronic Major Depression
Number of subjects: 212
Study: 2328551

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream with 2% topical minoxidil solution
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vehicle control cream with 2% topical minoxidil solution
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Skin biopsy analysis
Number of subjects: 19
Study: 535860

Group type: EXPERIMENTAL
Intervention: Piracetam (10 g i.v./h)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Laevulose (placebo infusion)
Number of subjects: 26
Study: 31473029

Group type: EXPERIMENTAL
Intervention: Collaborative Care Model for depression management
Number of subjects: 0
Study: 30972889

Group type: EXPERIMENTAL
Intervention: Dysglycemia Cluster 3 (n = 40, 17.1%)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: High HbA1c
Number of subjects: 234
Study: 28810895

Group type: EXPERIMENTAL
Intervention: Cluster randomised crossover design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sample size calculations for CRXO trials
Number of subjects: 0
Study: 24635059

Group type: EXPERIMENTAL
Intervention: Leisure education program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 24577773

Group type: EXPERIMENTAL
Intervention: Low pressure group (LP) with CO2 pneumoperitoneum pressure maintained at 8-10 mmhg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Middle pressure group (MP) with CO2 pneumoperitoneum pressure maintained at 11-13 mmhg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High pressure group (HP) with CO2 pneumoperitoneum pressure maintained at 14-16 mmhg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Open gastrectomy group (OG)
Number of subjects: 48
Study: 21476099

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Deep oscillation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (waiting group untreated for vasculopathy)
Number of subjects: 28
Study: 20456192

Group type: EXPERIMENTAL
Intervention: Topical capsaicin 0.1%
Number of subjects: 23

Group type: COMPARATOR
Intervention: Vaseline jelly
Number of subjects: 23
Study: 17408990

Group type: EXPERIMENTAL
Intervention: Superficial venous surgery plus compression
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Limited surgery under local anaesthesia (LA)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 185
Study: 15711989

Group type: EXPERIMENTAL
Intervention: Repeated bouts of 10‐s static stretches of the wrist flexors
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 57
Study: 12477473

Group type: EXPERIMENTAL
Intervention: Scheduled appointment for sigmoidoscopy by a nurse
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Instructed to call themselves for sigmoidoscopy
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Colonoscopy after sigmoidoscopy
Number of subjects: 2000
Study: 9422303

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with lidocaine 50 mg/ml 1.5‐2 ml in 7.5% glucose through a 27‐G Quincke needle (Group S)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with mepivacaine 20 mg/ml and epinephrine 5 microg/ml, 15‐20 ml (Group E)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Propofol anaesthesia with a bolus induction of 2 mg/kg followed by infusion (Group P)
Number of subjects: 91
Study: 8284627

Group type: EXPERIMENTAL
Intervention: Triple therapy (tetracycline 2 g, metronidazole 750 mg, bismuth subsalicylate 5 or 8 tablets) plus ranitidine 300 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ranitidine alone 300 mg
Number of subjects: 31
Study: 3542360

Group type: EXPERIMENTAL
Intervention: Ultraviolet light activated resin with a filler
Number of subjects: 1766

Group type: COMPARATOR
Intervention: Autopolymerizing resin without a filler
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: Carious teeth
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: Sound teeth
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: Premolars
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: Maxillary premolars
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: Resealed teeth after 1 year
Number of subjects: 1766
Study: 29458317

Group type: EXPERIMENTAL
Intervention: 1.5 kcal/mL enteral nutrition formulation
Number of subjects: 4000

Group type: COMPARATOR
Intervention: 1 kcal/mL enteral nutrition formulation
Number of subjects: 4000
Study: 27316705

Group type: EXPERIMENTAL
Intervention: iBeST (online training)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Face-to-face workshop (control group)
Number of subjects: 35
Study: 25749601

Group type: EXPERIMENTAL
Intervention: Strength After Breast Cancer exercise intervention
Number of subjects: 84
Study: 22221566

Group type: EXPERIMENTAL
Intervention: Barbed polyglyconate suture (V-Loc 180; Covidien)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard monofilament suture (4-0 poliglecaprone 25; Monocryl)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Barbed polyglyconate suture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard monofilament suture
Number of subjects: 70
Study: 20526196

Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 79
Study: 18842742

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral stress management (CBSM) intervention for 10 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: 1-day psychoeducation seminar (Control)
Number of subjects: 128
Study: 15838528

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) cycling at resistances of 0, 6.25, and 12.5 Watts (W)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cycling without FES at resistances of 0, 60, and 120 W
Number of subjects: 6
Study: 12068132

Group type: EXPERIMENTAL
Intervention: Dietary Intervention (DIET group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HRT + Dietary Intervention (HRT +DIET group)
Number of subjects: 24
Study: 10406828

Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Glyburide (20 mg/d)
Number of subjects: 22
Study: 8926537

Group type: EXPERIMENTAL
Intervention: 10 g of red pepper
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (without red pepper)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 g of red pepper with propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1747644

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate 120 mg four times a day for four weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg and amoxycillin 500 mg each three times a day for one week
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bismuth subcitrate 120 mg four times a day for four weeks, metronidazole 400 mg three times a day for one week, plus amoxycillin 500 mg three times a day for the first week
Number of subjects: 90
Study: 7107086

Group type: EXPERIMENTAL
Intervention: Spironothiazid (50 mg spironolactone, 50 mg hydrochlorothiazide)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Aldactone dragees (50 mg) plus Esidrex tablets (25 mg)
Number of subjects: 6
Study: 30328486

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with patients regarding trial participation factors
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with clinicians regarding recruitment factors
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trial retention
Number of subjects: 30
Study: 30293332

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3044

Group type: COMPARATOR
Intervention: Single aspirin
Number of subjects: 3044
Study: 26864127

Group type: EXPERIMENTAL
Intervention: D2-biofortified bread (25 µg D2/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: D2 supplement (25 µg D2/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: D3 supplement (25 µg D3/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo pill and regular bread (0 µg D2 or D3/d)
Number of subjects: 33
Study: 24674962

Group type: EXPERIMENTAL
Intervention: Active biofeedback treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham feedback (control)
Number of subjects: 21
Study: 22587791

Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% foam
Number of subjects: 659

Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 659
Study: 19492716

Group type: EXPERIMENTAL
Intervention: Low-shrinkage resin composite (InTen-S)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hybrid resin composite (Point 4)
Number of subjects: 50
Study: 17584007

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 4 days prior to hypoxia exposure
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo for 4 days prior to hypoxia exposure
Number of subjects: 8
Study: 15098799

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (240 ml, regular-strength)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bottled purified water (control)
Number of subjects: 20
Study: 12185799

Group type: EXPERIMENTAL
Intervention: Participation in worksite health-promotion program (n = 2596)
Number of subjects: 4189

Group type: COMPARATOR
Intervention: Nonparticipants (control group)
Number of subjects: 4189

Group type: EXPERIMENTAL
Intervention: Program participants
Number of subjects: 4189
Study: 9474534

Group type: EXPERIMENTAL
Intervention: Complete denture therapy procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procedural research in denture therapy
Number of subjects: 0
Study: 7857356

Group type: EXPERIMENTAL
Intervention: pidotimod 400 mg
Number of subjects: 235

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 235
Study: 2509605

Group type: EXPERIMENTAL
Intervention: MOR‐22 alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MOR‐22 and UFT (or FT‐207) in combination
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MOR‐22 prophylactically
Number of subjects: 42

Group type: COMPARATOR
Intervention: MOR‐22 and UFT (or FT‐207)
Number of subjects: 42
Study: 145237

Group type: EXPERIMENTAL
Intervention: Oral zinc
Number of subjects: 37

Group type: COMPARATOR
Intervention: Tetracyclines (oxytetracycline)
Number of subjects: 37
Study: 31549282

Group type: EXPERIMENTAL
Intervention: Nomogram developed using significant predictors (Primary tumor, Frankel Grade, Karnofsky Performance Score, adjuvant therapy)
Number of subjects: 244
Study: 27648629

Group type: EXPERIMENTAL
Intervention: L-Citrulline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26280756

Group type: EXPERIMENTAL
Intervention: Canagliflozin 25, 100, 200, or 400 mg (single dose and repeated doses for 14 days)
Number of subjects: 61